Stereotaxis (NYSEAMERICAN:STXS) Research Coverage Started at Citizens Jmp

Citizens Jmp assumed coverage on shares of Stereotaxis (NYSEAMERICAN:STXS) in a research report released on Tuesday morning, Marketbeat.com reports. The brokerage issued a market outperform rating and a $4.00 price objective on the stock.

A number of other research firms have also weighed in on STXS. UBS Group set a $4.00 price objective on shares of Stereotaxis in a research note on Wednesday, November 5th. Roth Capital reiterated a “buy” rating and set a $4.00 price objective on shares of Stereotaxis in a research note on Wednesday, November 12th. Finally, Citigroup initiated coverage on Stereotaxis in a report on Tuesday. They issued an “outperform” rating for the company. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $4.00.

Stereotaxis Price Performance

Shares of NYSEAMERICAN STXS opened at $2.32 on Tuesday. Stereotaxis has a 52 week low of $1.54 and a 52 week high of $3.59. The business’s 50 day moving average price is $2.62 and its 200 day moving average price is $2.58. The firm has a market cap of $216.50 million, a P/E ratio of -8.29 and a beta of 1.47.

Insider Buying and Selling at Stereotaxis

In related news, Director Paul J. Isaac purchased 20,000 shares of the stock in a transaction that occurred on Friday, November 14th. The shares were purchased at an average price of $2.24 per share, with a total value of $44,800.00. Following the completion of the acquisition, the director directly owned 2,786,557 shares in the company, valued at $6,241,887.68. This represents a 0.72% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 17.77% of the company’s stock.

Institutional Trading of Stereotaxis

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Kovack Advisors Inc. raised its holdings in Stereotaxis by 2.9% during the third quarter. Kovack Advisors Inc. now owns 137,855 shares of the company’s stock worth $429,000 after purchasing an additional 3,895 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Stereotaxis by 106.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock worth $36,000 after buying an additional 5,910 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Stereotaxis by 12.0% in the 3rd quarter. Bank of America Corp DE now owns 63,114 shares of the company’s stock valued at $196,000 after buying an additional 6,742 shares during the period. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Stereotaxis in the 3rd quarter valued at approximately $38,000. Finally, Moneta Group Investment Advisors LLC purchased a new stake in shares of Stereotaxis in the third quarter valued at approximately $43,000. Hedge funds and other institutional investors own 45.35% of the company’s stock.

About Stereotaxis

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.